Review

Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis

Wang, Leibo^a; Shi, Guanyu^b; Zhao, Guoqiang^a; He, Wei^a; Cen, Zhuangding^a; Xu, Feng^a

^aDepartment of Surgery, Guizhou Orthopaedic Hospital, Guiyang

^bDepartment of Urology, Fenggang County People’s Hospital, Zunyi, China

Received 20 September 2022 Revised form accepted 20 September 2022.

Correspondence to Leibo Wang, PhD, Department of Surgery, Guizhou Orthopaedic Hospital, Guiyang 550000, China, Tel: +18185243032; e-mail: [email protected]

Anti-Cancer Drugs 34(4):p 473-478, April 2023. | DOI: 10.1097/CAD.0000000000001449

Abstract

Full Text Access for Subscribers:

Individual Subscribers

Institutional Users

Access through Ovid^®

Not a Subscriber?

Buy

Request Permissions

You can read the full text of this article if you:

Access through Ovid

Article Level Metrics

Article Keywords

Keywords
advanced urothelial carcinoma , antibody-drug conjugate , bladder cancer , enfortumab vedotin , metastatic urothelial carcinoma

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Secondary Logo

Journal Logo

Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis